4.3 Drug & Dosage-Form Factors

4.3 Drug & Dosage-Form Factors

Quick Answer: The “right drug” can still fail or harm if the formulation, food timing, device, crushing practice, renal clearance, or brand/generic switch is wrong. Assess pharmacokinetic traps, IR vs MR behaviour, swallowing and device barriers, narrow therapeutic index risks, and Australian equivalence concepts before finalising a plan.

Standard 3.1 explicitly includes drug and dosage-form factors alongside patient factors. Intern Written items often turn on a formulation detail rather than the drug class headline.

Pharmacokinetic (PK) interactions that change management

PK interactions alter absorption, distribution, metabolism, or excretion — changing concentration without necessarily sharing the same receptor.

High-yield patterns:

Exam habit: When two medicines are both “reasonable alone,” ask whether concentration of one will rise or fall. Bleeding risk with anticoagulants can be PD (additive effect) or PK (level increase) — both matter, and counselling differs.

Always verify interaction severity and management in AMH under open-book conditions rather than relying on memory of every CYP pair.

Food effects

Food can increase, decrease, or delay absorption, or reduce GI irritation.

Counselling must be specific: “with breakfast” is better than “with food” if timing relative to other medicines matters. For bisphosphonates, incomplete counselling creates oesophagitis risk and treatment failure.

Formulation switches: IR vs MR (and related)

Immediate-release (IR) and modified-release (MR/SR/CR/XL — terminology varies by product) are not interchangeable on a milligram-for-milligram assumption without checking the product.

Key principles:

• MR products often cannot be crushed, chewed, or split unless the particular product allows it (some scored MR forms exist — verify).
• Switching IR ↔ MR usually requires prescriber-directed conversion, not pharmacy improvisation.
• MR aims for fewer daily doses or steadier levels; inappropriate IR substitution can cause peak toxicity or trough failure.
• “Burst” dumping from crushed MR opioids or other MR CNS drugs can be fatal — a critical safety teaching point.

Related formulation pitfalls:

• Enteric-coated products crushed → loss of protection, gastric irritation, or inactivation
• Sublingual / orodispersible products swallowed whole → altered onset
• Transdermal patches cut or heated → dose dumping or burns risk
• Different salt forms or combination products with similar names → wrong strength selection

Swallowing difficulties (dysphagia)

Dysphagia is common post-stroke, in Parkinson disease, head-and-neck disease, and frailty. Forcing large tablets risks aspiration and non-adherence.

Assessment:

• Solid oral dose problems vs liquids vs crushable forms
• Whether crushing is pharmaceutically appropriate
• Whether a licensed liquid, dispersible, patch, or alternative route exists
• Thickened fluids and interaction with medicine administration in aged care

Do not crush list mindset: If unsure, check product guidance and professional references before advising crushing. Recommend prescriber review for suitable alternatives when crushing is contraindicated.

Devices: inhalers, injectables, and technique-sensitive forms

Dosage form includes delivery devices.

Inhalers:

• pMDI vs DPI vs soft-mist — different inspiratory flow and coordination needs
• Spacer use for many pMDIs improves lung deposition and reduces oropharyngeal steroid exposure
• Device switches (even same molecule) require re-training
• “Empty” assessment: dose counters vs float tests (product-specific; avoid unsafe myths)

Injectables (patient-administered):

• Insulin pens: priming, needle length, site rotation, storage, cloudy insulin resuspension where relevant
• GLP-1 receptor agonist pens and other weekly injectables: day-of-week routines, missed-dose rules per product
• Adrenaline (epinephrine) autoinjectors: carry two when recommended, expiry checks, correct thigh administration, emergency plan after use

Other technique-sensitive forms: eye drops (nasolacrimal occlusion), nasal sprays, topical steroids (fingertip units, site potency), nicotine replacement formats.

Therapeutic failure is often device failure. Recheck technique before escalating dose.

Bioavailability traps

Bioavailability (fraction of dose reaching systemic circulation) is altered by:

1. Route and formulation — IV vs oral; MR vs IR; different products of same drug
2. First-pass metabolism — oral dose much higher than parenteral for some drugs
3. Food and binding interactions — as above
4. Crushing / mixing — destroying MR systems or adsorbing drug to enteral tubing
5. Brand or generic switches for critical-dose drugs — small AUC differences may matter clinically for a minority of agents
6. Gut integrity / vomiting / diarrhoea — oral absorption unreliable in acute illness

Practical pharmacy examples:

• Advising a patient to crush an MR nifedipine-type product (product-dependent) can cause dangerous hypotension from dose dumping — verify before any crush advice
• Levothyroxine absorption reduced by calcium/iron; separate by several hours
• Some oral bisphosphonates require strict fasting and posture rules for both safety and absorption

Renally cleared drugs

When clearance depends on kidney function, falling eGFR raises exposure and ADR risk.

Approach:

• Identify renally cleared or nephrotoxic agents in the regimen
• Obtain recent renal function when available; if missing and critical, do not guess high-risk doses
• Adjust dose/interval per AMH/product guidance or recommend prescriber adjustment
• Watch “triple whammy” patterns: ACE inhibitor/ARB + diuretic + NSAID → acute kidney injury risk
• Educate on sick-day considerations where clinically appropriate for selected medicines (per local guidance)

Renal dosing is both a drug factor and a patient factor — Standard 3.1 expects you to connect them.

Narrow therapeutic index (NTI) and high-vigilance medicines

NTI drugs have a small gap between effective and toxic concentrations. Management implications:

• Care with dose conversions and formulation changes
• Interaction checks are mandatory
• Therapeutic drug monitoring may be required (e.g. some antiepileptics, lithium, digoxin — context-specific)
• Brand consistency may be preferred for selected agents under clinical guidance
• Patient counselling on toxicity symptoms (e.g. digoxin toxicity features; lithium dehydration risk)

High-risk medicines more broadly (insulin, anticoagulants, opioids, chemotherapy oral agents, concentrated electrolytes in hospitals) deserve heightened double-checks even when not classically labelled NTI.

Australian brand and generic equivalence concepts

Australia’s regulatory framework supports generic substitution based on bioequivalence standards for many PBS medicines, enabling brand substitution policies in community pharmacy within legal and clinical limits.

Exam-level principles:

• Bioequivalence means the generic matches the reference for rate and extent of absorption within accepted statistical limits for approved substitutable products — it is not a claim of identical inactive ingredients or appearance.
• a-flagging / substitutable brands on the PBS schedule guide which brands may be substituted under PBS rules (know the concept; use current references in practice).
• Substitution still requires clinical judgement: patient confusion with different pack appearances, device changes for inhalers, allergy to excipients (rare but real), and critical-dose medicines where prescriber or guidelines prefer brand consistency.
• “Generic” is not lower quality by definition in the Australian regulated market; counselling should prevent unnecessary brand anxiety while respecting legitimate clinical exceptions.
• Different strengths, salts, or fixed-dose combinations are not automatic substitutes.

Patient-centred counselling on switches:

• Explain same active medicine and expected effect
• Show the pack and name on the label to reduce double-dosing when brands change
• Invite reporting of perceived efficacy/ADR changes — investigate seriously without dismissing

Integrating drug/form factors into the 3.1 process

When assessing options:

1. Is the molecule appropriate?
2. Is the form appropriate for swallow, device skill, and timing?
3. Do food/PK interactions break the plan?
4. Does renal/hepatic status change dose?
5. Is this an NTI/high-risk situation needing extra controls?
6. Will a brand/device switch confuse or destabilise therapy?

Mini-cases

Case A: Patient with dysphagia is prescribed an MR opioid tablet and family asks to crush it into yoghurt. Correct action is to refuse crushing MR opioid and contact the prescriber for a suitable formulation — crushing risks dose dumping.

Case B: Asthma symptoms worsen after a “same medicine” inhaler brand switch to a different device type. Prioritise technique training and device suitability before assuming disease progression alone.

Case C: Patient takes ciprofloxacin with an iron tablet every morning; infection is not improving. Separate chelating agents from the quinolone by appropriate intervals and reassess.

Drug and dosage-form mastery converts AMH lookup into safe, usable therapy — not just a correct drug name on a label.